Healthcare May 24, 2022 09:50 AM (GMT+8) · EqualOcean
Recently, Beijing shuoxing Biomedical Technology Co., Ltd. (hereinafter referred to as shuoxing Biology) announced that its self-developed nano multi antibody sm3321 has been approved by the FDA to carry out clinical research. Sm3321 is the world's first nano multi antibody drug approved by FDA for the treatment of acute myeloid leukemia (AML). Its approval of IND is an important milestone in the research and development of nano multi antibody biological drugs of shuoxing biology, which means that shuoxing biology has made a breakthrough in the field of nano antibody treatment. At the same time, the company will further accelerate the follow-up clinical research and development and commercialization process, and promote shuoxing biology to become a global leader in antibody biological drugs.